Clinical Trial Update: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial recruitment is ongoing for AZD5335 versus Mirvetuximab Soravtansine in FRα-high epithelial ovarian cancer and AZD5335 versus chemotherapy in FRα-l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• AZD5335 (AZD5335)
• Mirvetuximab soravtansine (mirvetuximab soravtansine)

Snippet

Sponsor: AstraZeneca | Conditions: Epithelial Ovarian Cancer | Phase 3 | Status: RECRUITING